Pierre Lao‐Sirieix

2.3k total citations
49 papers, 1.3k citations indexed

About

Pierre Lao‐Sirieix is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Pierre Lao‐Sirieix has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Surgery, 19 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Pierre Lao‐Sirieix's work include Esophageal Cancer Research and Treatment (29 papers), Gastric Cancer Management and Outcomes (17 papers) and Helicobacter pylori-related gastroenterology studies (13 papers). Pierre Lao‐Sirieix is often cited by papers focused on Esophageal Cancer Research and Treatment (29 papers), Gastric Cancer Management and Outcomes (17 papers) and Helicobacter pylori-related gastroenterology studies (13 papers). Pierre Lao‐Sirieix collaborates with scholars based in United Kingdom, United States and Spain. Pierre Lao‐Sirieix's co-authors include Rebecca C. Fitzgerald, Laurence Lovat, Maria O’Donovan, Marco Novelli, I. Debiram, Alex Boussioutas, Sudarshan Kadri, Madhumita Das, Elizabeth Bird‐Lieberman and Fiona M Walter and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Pierre Lao‐Sirieix

47 papers receiving 1.3k citations

Peers

Pierre Lao‐Sirieix
Shouji Shimoyama Japan
Yukinori Yamagata Japan
Elizabeth Bird‐Lieberman United Kingdom
Agnieszka Magdalena Rygiel Netherlands
Masayuki Shinkai Japan
Takekazu Yamao Japan
Futoshi Miyazono Japan
Putao Cen United States
Takuhiro Kohsaki Japan
Shouji Shimoyama Japan
Pierre Lao‐Sirieix
Citations per year, relative to Pierre Lao‐Sirieix Pierre Lao‐Sirieix (= 1×) peers Shouji Shimoyama

Countries citing papers authored by Pierre Lao‐Sirieix

Since Specialization
Citations

This map shows the geographic impact of Pierre Lao‐Sirieix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Lao‐Sirieix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Lao‐Sirieix more than expected).

Fields of papers citing papers by Pierre Lao‐Sirieix

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Lao‐Sirieix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Lao‐Sirieix. The network helps show where Pierre Lao‐Sirieix may publish in the future.

Co-authorship network of co-authors of Pierre Lao‐Sirieix

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Lao‐Sirieix. A scholar is included among the top collaborators of Pierre Lao‐Sirieix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Lao‐Sirieix. Pierre Lao‐Sirieix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2025). Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel). Transplantation and Cellular Therapy. 31(2). S216–S217. 1 indexed citations
2.
Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2024). Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes. Blood. 144(Supplement 1). 963–963. 1 indexed citations
3.
4.
Jones, Melanie A., Kirsten M. Timms, Elizabeth S. Cogan, et al.. (2023). The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing. Genes Chromosomes and Cancer. 62(10). 589–596. 3 indexed citations
5.
Redman, James E., Lorenz Wernisch, Richard Newton, et al.. (2016). The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma. Cancer Prevention Research. 9(7). 558–566. 20 indexed citations
6.
Silva, Nadeera de, Anna Paterson, Maria Secrier, et al.. (2015). Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. British Journal of Cancer. 113(9). 1305–1312. 17 indexed citations
7.
Varghese, Sybil, Richard Newton, Caryn S. Ross-Innes, et al.. (2015). Analysis of Dysplasia in Patients With Barrett’s Esophagus Based on Expression Pattern of 90 Genes. Gastroenterology. 149(6). 1511–1518.e5. 19 indexed citations
8.
Roshandel, Gholamreza, Shahin Merat, Masoud Sotoudeh, et al.. (2014). Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. British Journal of Cancer. 111(12). 2235–2241. 31 indexed citations
9.
Shannon, Nicholas B., Pierre Lao‐Sirieix, Caryn S. Ross-Innes, et al.. (2012). OC-017 TRIM44: from prognosis to therapy in oesophageal adenocarcinoma and breast cancer. Gut. 61(Suppl 2). A8.1–A8. 1 indexed citations
10.
Bird‐Lieberman, Elizabeth, Jason Dunn, Helen G. Coleman, et al.. (2012). Population-Based Study Reveals New Risk-Stratification Biomarker Panel for Barrett's Esophagus. Gastroenterology. 143(4). 927–935.e3. 117 indexed citations
11.
Shariff, Mohammed, Massimiliano di Pietro, David F. Boerwinkel, et al.. (2012). 958 Time: A Prospective Study Combining Endoscopic Trimodal Imaging and Molecular Endpoints to Improve Risk Stratification in Barrett's Esophagus. Gastroenterology. 142(5). S–165. 5 indexed citations
12.
Bird‐Lieberman, Elizabeth, Jason Dunn, Pierre Lao‐Sirieix, et al.. (2011). Phase 2 and phase 3 multicentre studies demonstrate the potential for glycans as predictive biomarkers in barrett's oesophagus. Gut. 60(Suppl 1). A169.3–A170. 1 indexed citations
13.
Dunn, Jason, Elizabeth Bird‐Lieberman, Helen G. Coleman, et al.. (2011). * Image cytometry DNA ploidy abnormalities are an independent risk factor for cancer progression in non-dysplastic barrett's oesophagus and low grade dysplasia: results of the NIBR study. Gut. 60(Suppl 1). A172.3–A173. 1 indexed citations
14.
Lao‐Sirieix, Pierre, Carlos Caldas, & Rebecca C. Fitzgerald. (2010). Genetic predisposition to gastro-oesophageal cancer. Current Opinion in Genetics & Development. 20(3). 210–217. 41 indexed citations
15.
Lao‐Sirieix, Pierre, Alex Boussioutas, Sudarshan Kadri, et al.. (2009). Non-endoscopic screening biomarkers for Barrett’s oesophagus: from microarray analysis to the clinic. Gut. 58(11). 1451–1459. 90 indexed citations
16.
Lao‐Sirieix, Pierre, Laurence Lovat, & Rebecca C. Fitzgerald. (2007). Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus Surveillance. Clinical Cancer Research. 13(2). 659–665. 57 indexed citations
17.
Lao‐Sirieix, Pierre, Andrej Ćorović, Janusz Jankowski, et al.. (2007). Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. Diseases of the Esophagus. 21(6). 529–538. 16 indexed citations
18.
Lao‐Sirieix, Pierre & Rebecca C. Fitzgerald. (2006). Surveillance and screening of Barrett's oesophagus. British Journal of Hospital Medicine. 67(7). 355–359. 1 indexed citations
19.
Aitchison, Alan, Suet‐Feung Chin, Ian G. Mills, et al.. (2005). Impaired transforming growth factor β signalling in Barrett’s carcinogenesis due to frequent SMAD4 inactivation. Gut. 55(6). 764–774. 51 indexed citations
20.
Lao‐Sirieix, Pierre, Rebecca Brais, Laurence Lovat, Nicholas Coleman, & Rebecca C. Fitzgerald. (2004). Cell Cycle Phase Abnormalities Do Not Account for Disordered Proliferation in Barrett's Carcinogenesis. Neoplasia. 6(6). 751–760. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shouji Shimoyama Breakdown of academic impact, for papers by Yukinori Yamagata Breakdown of academic impact, for papers by Elizabeth Bird‐Lieberman Breakdown of academic impact, for papers by Agnieszka Magdalena Rygiel Breakdown of academic impact, for papers by Masayuki Shinkai Breakdown of academic impact, for papers by Takekazu Yamao Breakdown of academic impact, for papers by Futoshi Miyazono Breakdown of academic impact, for papers by Putao Cen Breakdown of academic impact, for papers by Takuhiro Kohsaki
Rankless by CCL
2026